Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study by NDM researchers and collaborators has found methaemoglobin levels during treatment for vivax malaria could be used to predict whether a patient would have recurrent malaria.

Residents in the northern mountain region of Vietnam © Simone D. McCourtie / World Bank

Researchers conducted an individual patient data meta-analysis using data from 1,747 patients, across Indonesia, Brazil, Vietnam, Thailand, Peru, Colombia, Ethiopia, and India, between 2000 to 2022, to examine the utility and validity of blood methaemoglobin as a measure for people having recurrent vivax malaria.

Plasmodium vivax malaria is dangerous because parasites can lay dormant in the liver for weeks or years and then cause serious recurrence or death. The prodrugs primaquine and tafenoquine are the only available treatments to prevent relapsing malaria, but their optimal dosing remains unclear.

Analysis of the data showed that methaemoglobin levels during treatment for vivax malaria can be used to predict population-level treatment efficacy. However, further research is needed to determine if this marker can be used to predict recurrence at an individual patient level.

Researchers observed an increasing dose-response relationship between weight-adjusted primaquine dose and methaemoglobin levels measured on day seven. They found that, for a fixed primaquine dose regimen, a doubling of day seven methaemoglobin was associated with an estimated 30% reduction in the risk of vivax recurrence. Using day seven methaemoglobin levels as a surrogate endpoint for recurrent malaria could reduce sample sizes needed in future studies by about 40% and shorten the follow-up duration by 94%.

Dr Ihsan Fadilah, based at NDM's Oxford University Clinical Research Unit Indonesia and Centre for Tropical Medicine and Global Health and first author of the study, said 'This study could be used to refine guidelines for the design of exploratory trials or to consider incorporating methaemoglobin measurement in malaria control programmes. It highlights a promising, measurable approach to optimise malaria treatment efficacy, which could eventually inform policy in specific settings.'

The full paper, titled 'Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis', is available on the PLOS Medicine website.

Similar stories

Two new MRC Centres to create cutting-edge gene therapies

The Medical Research Council (MRC), part of UKRI, is launching its first two Centres of Research Excellence (CoRE), which will develop transformative new advanced therapeutics for currently untreatable diseases. Oxford is leading one of these Centres and co-leading the other. Together, these international collaborations will receive up to £50 million each over 14 years.